In this prospective cohort study of postmenopausal women who used AIs to treat early stage hormone receptor-positive BC, longer duration of AI use was associated with lower risks of stroke, all-cause mortality, CVD-related mortality, and non-CVD-related mortality. This evidence concerns the gene NR4A1 and breast cancer.